Oxford Science Enterprises — 2023 Investments
6 investments dated 2023 · listed companies and verified rows first · show all
AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
BiotechDeep TechDigital HealthHealthtechMedical Devices
David Hipkiss(Executive Chair)in
Co-investorsOld College Capital
BehaVR develops VR-based (XR) therapeutics for mental and behavioral health, translating clinical science into immersive programs that address stress, anxiety, fear, pain management, addiction recovery, and maternal health.
Digital HealthHealthtechMental HealthElizabethtown, US
Aaron Gani(Executive Officer, Director)
Co-investorsChrysalis VenturesKeyhorse CapitalPoplar VenturesAccenture VenturesFrist Cressey VenturesFuture Labs Capital+1 more
University of Oxford spinout whose imaging technology aids diagnosis and treatment of cardiovascular disease.
Co-investorsBusiness Growth FundCreative Destruction Lab (CDL)Longwall Venture Partners LLPOxford Investment Consultants LLP
Oxford Ionics develops trapped-ion quantum computers using proprietary Electronic Qubit Control technology, designed for businesses to deploy quantum computing applications.
Deep TechHardwareQuantum Computing
Co-investorsOxford University Innovation2xNBraavos CapitalLansdowne PartnersProsus VenturesProvidence Investment Company Limited
Prolific operates a platform that connects research teams with a vetted pool of participants to collect high-quality human-powered data at scale, used for academic and industry research as well as developing and training AI models.
AI & Machine LearningData & InfrastructureEnterprise SoftwareMarketplacesSaaSLondon, GB
Phelim Bradley(CTO)inSam Harman(Director)Enrico D'Angelo(Director)Meenakshi Parameshwaran(Data Scientist)Matt Tuplin(Vice President of Engineering)Chloe Sheppard(Talent Manager)
Co-investors10xvaluepartnersY CombinatorAltaclub VCAltaIR CapitalPartech VenturesPioneer
Prolific operates an online platform connecting researchers and AI/ML developers with verified human participants who complete paid studies, providing human data and feedback for research and for AI tasks like preference tuning, safety evaluations, and benchmarks.
AI & Machine LearningData & InfrastructureMarketplaces
Co-investorsPartech VenturesPioneer
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




















